Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/6/2019
SIETES contiene 92761 citas

 
 
 1 a 20 de 100 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events. JAMA Surgery 2019:24 de abril. [Ref.ID 103091]
2.Enlace a cita original
Nielen JTH, de Vries F, Dagnelie PC, van den Bemt BJF, Emans PJ, Lalmohamed A, de Boer A, Boonen A. Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case–control study. Br J Clin Pharmacol 2016;81:370-8. [Ref.ID 100098]
3.Tiene citas relacionadas Cita con resumen
Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ 2014;349:g4829. [Ref.ID 98189]
4.Tiene citas relacionadas Cita con resumen
Ker K, Roberts I. Tranexamic acid for surgical bleeding. BMJ 2014;349:g4934. [Ref.ID 98188]
5.Tiene citas relacionadas Cita con resumen
Hunt LP, Ben-Shlomo Y, Clark EM, Dieppe P, Judge A, MacGregor AJ, Tobias JH, Vernon K, Blom AW, on behalf of the National Joint Registry for England Wales and Northern Ireland. 90-day mortality after 409 096 total hip replacements for osteoarthritis, from the National Joint Registry for England and Wales: a retrospective analysis. Lancet 2013;382:1097-104. [Ref.ID 96311]
6.Tiene citas relacionadas Cita con resumen
Issa K, Mont MA. Total hip replacement: mortality and risks. Lancet 2013;382:1074-6. [Ref.ID 96310]
7. Cita con resumen
Lalmohamed A, Vestergaard P, Klop C, Grove EL, de Voer A, Leufkens HGM, van Staa TP, de Vries F. Timing of acute myocardial infarction in patients undergoing total hip or knee replacement. A nationwide cohort study. Arch Intern Med 2012;172:1229-35. [Ref.ID 94317]
8. Cita con resumen
Gómez Arrayas I, Suárez Fernández C, Gómez Cerezo JF, Betegón Nicolás L, de Salas-Cansado M, Rubio-Terrés C. Impacto presupuestario para el Sistema Nacional de Salud de la prevención del tromboembolismo venoso con apixaban en pacientes sometidos a artroplastia total de rodilla o cadera. Rev Esp Salud Pública 2012;86:601-12. [Ref.ID 93269]
9.Tiene citas relacionadas
Carrier M, Cushman M. Assessing the utility of venous thrombosis prophylaxis in orthopedic surgery patients. Ann Intern Med 2012;156:748-9. [Ref.ID 92955]
10.Tiene citas relacionadas Cita con resumen
Sobieraj DM, Lee S, Coleman CI, Tongbram V, Chen W, Colby J, Kluger J, Makanji S, Ashaye AO, White CM. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. Ann Intern Med 2012;156:720-7. [Ref.ID 92954]
11.Tiene citas relacionadas Cita con resumen
Neumann I, Rada G, Claro JC, Carrasco-Labra A, Thorlund K, Akl EA, Bates SM, Guyatt GH. Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med 2012;156:710-9. [Ref.ID 92953]
12. Cita con resumen
Jämsen E, Nevalainen P, Eskelinen A, Huotari K, Kalliovalkama J, Moilanen T. Obesity, diabetes, and preoperative hyperglycemia as predictors of periprosthetic joint infection: a single-center analysis of 7181 primary hip and knee replacements for osteoarthritis. J Bone Joint Surg Br 2012;94:e1011. [Ref.ID 92901]
14.Tiene citas relacionadas Cita con resumen
Januel J-M, Chen G, Ruffieux C, Quan H, Douketis JD, Crowther MA, Colin C, Ghali WA, Burnand B, for the IMECCHI Group. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee artrhoplasthy among patients receiving recommended prophylaxis: a systematic review. JAMA 2012;307:294-303. [Ref.ID 92228]
15. Cita con resumen
Prieto-Alhambra D, Javaid MK, Judge A, Murray D, Carr A, Cooper C, Arden NK. Association between bisphosphonate use and implant survival after primary total athroplasty of the knee or hip: population based retrospective cohort study. BMJ 2011;343:d7222. [Ref.ID 91899]
16. Cita con resumen
17.Enlace a cita original
Eikelboom JW, Weitz JI. New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. BMJ 2011;342:224-7. [Ref.ID 90144]
18.Enlace a cita original Cita con resumen
Cao YB, Zhang JD, Shen H, Jiang YY. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010;66:1099-108. [Ref.ID 89585]
19. Cita con resumen
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, and the ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15. [Ref.ID 88035]
20.Tiene citas relacionadas Cita con resumen
Sweetland S, Green J, Liu B, Berrinton de González A, Canonico M, Reeves G, Beral V, on benalf of the Million Women Study collaborators. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 2010;340:32. [Ref.ID 87667]
Seleccionar todas
 
 1 a 20 de 100 siguiente >>